CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

MYRIAD GENETICS INC

MYGN
$2.22B
Mid Cap
NASDAQIn Vitro & In Vivo Diagnostic SubstancesHealthcare🇺🇸North AmericaSALT LAKE CITY2.7K employees

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.

Website

Drugs in Pipeline

0

Phase 3 Programs

0

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

MYGN News
Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Drug Pipeline

No drugs found in this phase.

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply